T

TG Therapeutics
D

TGTX

30.900
USD
-0.04
(-0.13%)
مغلق
حجم التداول
72,973
الربح لكل سهم
1
العائد الربحي
-
P/E
-310
حجم السوق
4,810,058,821
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRVS
    -0.22000
    (-4.99%)
    4.19000 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    K
    KPTI
    -0.00940
    (-1.55%)
    0.59840 USD
    P
    PBYI
    -0.01500
    (-0.51%)
    2.90500 USD
    المزيد
الأخبار
المقالات

العنوان: TG Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.